国药一致公告，预计2025年度实现归属于上市公司股东的净利润10.55亿元到12.15亿元，同比增长 64.20%到89.11%。预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利润9.96亿元到 11.56亿元，同比增长71.38%到98.91%。 ...

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2026-01 二、与会计师事务所沟通情况 国药一致（简称"公司"）就业绩预告有关事项已与会计师事务所进行预沟 通，公司与会计师事务所在业绩预告方面不存在分歧。本次业绩预告相关的财务 数据是公司财务部门初步估算得出，未经会计师事务所审计。 国药集团一致药业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日至2025年12月31日。 （二）业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 | 归属于上市公司股 东的净利润 | 盈利：105,500万元-121,500万元 | 盈利：64,249.34万元 | | --- | --- | --- | | | 比上年同期增长：64.20%-89.11% | | | 扣除非经常性损益 后的净利润 | 盈利：99,600万元-115,600万元 | 盈利：58,117.72万元 | | | 比上年同期增长：71.38%-98.91 ...

Group 1 - The core viewpoint of the article is that the company, Guoyao Yici, has acknowledged a significant funding requirement in its pharmaceutical distribution segment, which has led to an increase in accounts receivable due to external environmental impacts [1] - The company's goodwill is primarily associated with its pharmaceutical retail segment, and it conducts annual impairment tests on asset groups that include goodwill, in accordance with accounting standards and company policies [1] - The results of the impairment tests determine whether the company needs to recognize any impairment losses, thereby accurately reflecting the value of goodwill assets [1]

Core Viewpoint - The company emphasizes the importance of modern logistics construction to support its pharmaceutical distribution business, highlighting its logistics system as a core competitive advantage for business development [1]. Group 1 - The company has a strong focus on logistics modernization, which is crucial for its pharmaceutical distribution operations [1]. - The existing logistics system, including the smart logistics warehouse in Shenzhen, has become a key competitive advantage for the company's business growth [1].

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), has enhanced its operational quality through strategic adjustments in its procurement system, product structure, and store layout [1] Group 1 - The company has strengthened its procurement system to improve operational efficiency [1] - There has been an optimization of the product structure to better meet market demands [1] - Strategic adjustments in store layout have been implemented to enhance overall business performance [1]

证券日报网讯1月21日，国药一致（000028）在互动平台回答投资者提问时表示，根据会计准则，公司 以预期信用损失为基础，对应收账款进行减值测试并确认减值准备。公司高度重视应收账款风险管控， 将从严资信管理、强化业务源头管控、加强应收账款催收和考核力度等方面不断完善应收账款监控机 制，降低应收风险。 ...

证券日报网讯1月21日，国药一致（000028）在互动平台回答投资者提问时表示，根据企业会计准则和 公司会计政策的相关规定，公司每年对包含商誉的资产组进行减值测试，并根据减值测试结果确定是否 需计提减值，如实反映商誉资产价值。 ...

证券日报网讯1月21日，国药一致（000028）在互动平台回答投资者提问时表示，受多种因素影响，医 药分销行业应收账款周期出现普遍性延长，公司努力加强对应收账款的管理，从采购、融资、付款等各 环节入手，保持公司运营稳健。 ...

Group 1 - The core viewpoint of the news is that Guoyao Yicai's subsidiary, Guoyao Holdings Guangxi Co., has received approval for the environmental assessment of its radioactive drug storage project, with a total investment of 995,000 yuan [1] - The "A-share Green Report" project aims to enhance the transparency of environmental information for listed companies, utilizing authoritative environmental regulatory data from 31 provinces and 337 cities [1] - The latest A-share Green Weekly Report indicated that six listed companies have recently exposed environmental risks [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]